Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Assets Average (2017 - 2025)

UroGen Pharma (URGN) has disclosed Assets Average for 8 consecutive years, with $192.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets Average fell 34.4% year-over-year to $192.8 million, compared with a TTM value of $192.8 million through Dec 2025, down 34.4%, and an annual FY2025 reading of $243.1 million, up 4.77% over the prior year.
  • Assets Average was $192.8 million for Q4 2025 at UroGen Pharma, down from $196.9 million in the prior quarter.
  • Across five years, Assets Average topped out at $293.8 million in Q4 2024 and bottomed at $104.2 million in Q2 2023.
  • Average Assets Average over 5 years is $176.7 million, with a median of $150.2 million recorded in 2022.
  • The sharpest move saw Assets Average crashed 40.59% in 2021, then soared 131.58% in 2024.
  • Year by year, Assets Average stood at $127.2 million in 2021, then rose by 3.83% to $132.0 million in 2022, then surged by 40.84% to $186.0 million in 2023, then surged by 58.0% to $293.8 million in 2024, then crashed by 34.4% to $192.8 million in 2025.
  • Business Quant data shows Assets Average for URGN at $192.8 million in Q4 2025, $196.9 million in Q3 2025, and $228.2 million in Q2 2025.